PROGRESSION OF CAROTID ARTERY ATHEROSCLEROSIS DURING TREATMENT TO TARGET IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a disease with a high cardiovascular risk. The results of works on the impact of antirheumatic therapy on carotid artery (CA) intima-media thickness (IMT) are contradictory. Objective: to assess the time course of changes in CA IMT and CA atherosclerosis (CAA) in patients with early RA during treatment to target at a 18-month follow-up. Subjects and methods. The investigation enrolled patients with early RA (disease duration of less than 12 months), who had not previously taken disease-modifying antirheumatic drugs and glucocorticoids. Duplex scanning (DS) of the CA was performed with IMT measurement at baseline and at 18 months after treatment. Vascular atherosclerotic lesion was recorded when atherosclerotic plaque (ASP) was detected. Starting methotrexate (MTX) monotherapy was prescribed to all the patients, when it showed an insufficient effect at 3 months, a biological agent (BA), such as a tumor necrosis factor-α inhibitor or abatacept, was added. RA remission was noted in 31 (42%) patients at 18 months of treatment. Results and discussion. The investigation included 74 patients with early RA; whose median (Me) age was 56 years, all the patients had moderate or high disease activity (Me DAS28-ESR, 5.4). At baseline, there was increased CA IMT in 51.4% of cases and CAA in 55.4%. At 18 months of treatment, there were no significant IMT changes. New CA ASPs were recorded in 8 (24.2%) patients who had no CAA at the time of inclusion in the investigation (p < 0.05). Nineteen (46.3%) patients were recorded to have the progression that had been identified when including CAA as a considerable increase in the number of ASPs (p < 0.05). The risk of CAA progression was correlated inversely with the mean 18-month level of high-density lipoprotein cholesterol (HDL-Cmean) and directly with the mean concentration of C-reactive protein (CRPmean). There was no significant correlation between HDL-Cmean and CRPmean. The changes of CAA were unassociated with the value of DAS28-ESR, the achievement of RA remission, and antirheumatic therapy (MTX monotherapy, MTX + BA). Conclusion. CAA shows progress in patients with early RA despite they are treated to target. DAS28-ESR remission in RA and ongoing RA treatment option had no substantial impact on the course of CAA. HDL-Cmean and CRPmean are independent risk factors for progression of CAA.

1. Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guidelance]. Moscow: GEOTAR-Media; 2008. P. 290-331 (In Russ.)

2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Pineiro A, et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1219-23.

3. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482-7. doi: 10.1136/ard.2010.135871

4. Gepner AD, Young R, Delaney JA, et al. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid inti-ma-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging. 2015 Jan;8(1). pii: e002262. doi: 10.1161/CIRCIMAGING.114.002262

5. Ikdahl E, Rollefstad S, Wibetoe G, et al. Predictive Value of Arterial Stiffness and Subclinical Carotid Atherosclerosis for Cardiovascular Disease in Patients with Rheumatoid Arthritis. J Rheumatol. 2016 Sep;43(9):1622-30. doi: 10.3899/jrheum.160053

6. Ambrosino P, Lupoli R, Di Minno A, et al. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015 May;113(5):916-30.

7. doi: 10.1160/TH14-11-0921

8. Lu L, Choi HK, Schoenfeld SR, et al. Improved survival in rheumatoid arthritis: a general population-based study. Ann Rheum Dis. 2015;74:137-8. doi: 10.1136/annrheumdis-2015-eular.3507

9. Kerola AM, Nieminen TV, Virta LJ, et al. No increased cardiovascular mortality among early rheumatoid arthritis patients:

10. a nationwide register study in 2000–2008. Clin Exp Rheumatol. 2015 May-Jun;33(3):391-8.

11. Georgiadis A, Voulgari PV, Argyropoulou MI, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum. 2008 Aug;38(1):13-9. doi: 10.1016/j.semarthrit.2007.09.008

12. Guin A, Chatterjee Adhikari M, Chakraborty S, et al. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum. 2013 Aug;43(1):48-54. doi: 10.1016/j.semarthrit.2012.12.027

13. Raczkiewicz A, Juszkiewicz A, Kisiel B, et al. Treat-to-target therapy does not prevent excessive progression of carotid intima media thickness during the first year of therapy in early rheumatoid arthritis. Arch Med Sci Atheroscler Dis. 2016;1:e36-e43.

14. doi: 10.5114/amsad.2016.60225

15. Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):117-25 (In Russ.)]. doi: 10.14412/1995-4484-2013-637

16. National recommendations for cardiovascular prophylaxis. Committee of Experts RCS. Kardiovaskulyarnaya Terapiya i Profilaktika. Suppl.2. 2011;10(6):46 (In Russ.)

17. Working Group for the Treatment of Stable Coronary Heart Disease of the European Society of Cardiology (ESC). Recommendations for the treatment of stable ischemic heart disease. ESC 2013. Rossiyskiy Kardiologicheskiy Zhurnal. 2014;7(111):7-79 (In Russ.)

18. Ministry of Health of the Russian Federation; Russian Association of Endocrinologists; FGBU Endocrinology Research Center. Dedov II, Shestakova MV, editors. Algorithms of special-ized medical care for patients with diabetes mellitus. Suppl. 6. Moscow; 2013 (In Russ.)

19. Olyunin YuA. Evaluation of the activity and effectiveness of therapy for rheumatoid arthritis. International indices for assessing the activity, functional status and quality of life of patients with rheumatic diseases. Moscow: Publishing Group of the Association of Rheumatologists of Russia; 2007. P. 3-12 (In Russ.)

20. Russian Cardiology Society. National Society for the Study of Atherosclerosis. Russian Society of Cardiosomal Rehabilitation and Secondary Prevention. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations (V revision). Moscow; 2012. Section 3. Patient examination and risk assessment of cardiovascular complications (In Russ.)

21. Hannawi S, Haluska B, Marwick TH, Thomas R. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther. 2007;9(6):R116.

22. doi: 10.1186/ar2323

23. Boytsov SA, Kukharchuk VV, Karpov YuA, et al. Subclinical atherosclerosis as a risk factor for cardiovascular complications. Kardiovaskulyarnaya Terapiya i Profilaktika. 2012;11(3):82-6 (In Russ.)

24. Chironi G, Gariepy J, Denarie N, et al. Influence of hypertension on early carotid artery remodeling. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1460-4. doi: 10.1161/01.ATV.0000083342.98342.22

25. Gorbunova YuN, Novikova DS, Popkova TV, et al. Cardiovascular risk in patients with early rheumatoid arthritis before disease-modifying antirheumatic therapy (preliminary data of the REMARCА study). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):381-6 (In Russ.)]. doi: 10.14412/1995-4484-2014-381-386

26. Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin-Induced Carotid Plaque Regression in Patients With Inflammatory Joint Diseases: The Rosuvastatin in Rheumatoid Arthritis, Ankylosing Spondylitis and Other Inflammatory Joint Diseases Study. Arthritis Rheum. 2015 Jul;67(7):1718-28. doi: 10.1002/art.39114

27. Pereira IA, Laurindo IM, Zimmermann AF, et al. Single measurements of C-reactive protein and disease activity scores are not predictors of carotid atherosclerosis in rheumatoid arthritis patients. Acta Reumatol Port. 2009 Jan-Mar;34(1):58-64.

28. Pope JE, Nevskaya T, Barra L, Parraga G. Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. Open Rheumatol J. 2016;10:49-59. doi: 10.2174/1874312901610010049

29. Arida A, Protogerou AD, Konstantonis G, et al. Atherosclerosis is not accelerated in rheumatoid arthritis of low activity or remission, regardless of antirheumatic treatment modalities. Rheumatology (Oxford). 2017 Jun 1;56(6):934-9. doi: 10.1093/rheumatology/kew506

30. Sö dergren A, Karp K, Bengtsson C, et al. The Extent of Subclinical Atherosclerosis Is Partially Predicted by the Inflammatory Load: A Prospective Study over 5 Years in Patients with Rheumatoid Arthritis and Matched Controls. J Rheumatol. 2015 Jun;42(6):935-42. doi: 10.3899/jrheum.140694

31. Giles JT, Post WS, Blumenthal RS, et al. Longitudinal Predictors of Progression of Carotid Atherosclerosis in Rheumatoid Arthritis. Arthritis Rheum. 2011 Nov;63(11):3216-25. doi: 10.1002/art.30542